140 related articles for article (PubMed ID: 33478285)
1. Novel anti-PD-L1 peptide selected from combinatorial phage library inhibits tumor cell growth and restores T-cell activity.
Tooyserkani R; Rasaee MJ; Bandehpour M; W P M Löwik D
J Drug Target; 2021 Aug; 29(7):771-782. PubMed ID: 33478285
[TBL] [Abstract][Full Text] [Related]
2. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy.
Liu H; Zhao Z; Zhang L; Li Y; Jain A; Barve A; Jin W; Liu Y; Fetse J; Cheng K
J Immunother Cancer; 2019 Oct; 7(1):270. PubMed ID: 31640814
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
[TBL] [Abstract][Full Text] [Related]
4. Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction.
Boohaker RJ; Sambandam V; Segura I; Miller J; Suto M; Xu B
Cancer Lett; 2018 Oct; 434():11-21. PubMed ID: 29920293
[TBL] [Abstract][Full Text] [Related]
5. A PD-1 peptide antagonist exhibits potent anti-tumor and immune regulatory activity.
Tao H; Cheng L; Liu L; Wang H; Jiang Z; Qiang X; Xing L; Xu Y; Cai X; Yao J; Wang M; Qiu Z
Cancer Lett; 2020 Nov; 493():91-101. PubMed ID: 32805322
[TBL] [Abstract][Full Text] [Related]
6. Phage display-identified PD-L1-binding peptides reinvigorate T-cell activity and inhibit tumor progression.
Gurung S; Khan F; Gunassekaran GR; Yoo JD; Poongkavithai Vadevoo SM; Permpoon U; Kim SH; Kim HJ; Kim IS; Han H; Park JH; Kim S; Lee B
Biomaterials; 2020 Jul; 247():119984. PubMed ID: 32278214
[TBL] [Abstract][Full Text] [Related]
7. Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells.
Yuan LW; Jiang XM; Xu YL; Huang MY; Chen YC; Yu WB; Su MX; Ye ZH; Chen X; Wang Y; Lu JJ
Phytomedicine; 2021 Jan; 80():153394. PubMed ID: 33130472
[TBL] [Abstract][Full Text] [Related]
8. Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells.
Coombs MRP; Harrison ME; Hoskin DW
Cancer Lett; 2016 Oct; 380(2):424-433. PubMed ID: 27378243
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 4-phenyl-1H-indazole derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction.
Xu C; Sun Z; Zhang X; Zang Q; Yang Z; Li L; Yang X; He Y; Ma Z; Chen J
Bioorg Chem; 2024 Jun; 147():107376. PubMed ID: 38640722
[TBL] [Abstract][Full Text] [Related]
11. In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1.
Zhai W; Zhou X; Du J; Gao Y
Methods Enzymol; 2019; 629():361-381. PubMed ID: 31727249
[TBL] [Abstract][Full Text] [Related]
12. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
13. Metformin Liposome-Mediated PD-L1 Downregulation for Amplifying the Photodynamic Immunotherapy Efficacy.
Xiong W; Qi L; Jiang N; Zhao Q; Chen L; Jiang X; Li Y; Zhou Z; Shen J
ACS Appl Mater Interfaces; 2021 Feb; 13(7):8026-8041. PubMed ID: 33577301
[TBL] [Abstract][Full Text] [Related]
14. Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer.
Zhang J; Zhou Q; Xie K; Cheng L; Peng S; Xie R; Liu L; Zhang Y; Dong W; Han J; Huang M; Chen Y; Lin T; Huang J; Chen X
J Exp Clin Cancer Res; 2021 Jun; 40(1):203. PubMed ID: 34154613
[TBL] [Abstract][Full Text] [Related]
15. Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect.
Gao T; Mao Z; Li W; Pei R
J Mater Chem B; 2021 Jan; 9(3):746-756. PubMed ID: 33319876
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and pharmacological evaluation of novel resorcinol biphenyl ether analogs as small molecule inhibitors of PD-1/PD-L1 with benign toxicity profiles for cancer treatment.
Cao H; Cheng B; Liu T; Chen J
Biochem Pharmacol; 2021 Jun; 188():114522. PubMed ID: 33741334
[TBL] [Abstract][Full Text] [Related]
17. Discovery of hPRDX5-based peptide inhibitors blocking PD-1/PD-L1 interaction through in silico proteolysis and rational design.
Zou S; Liu J; Sun Z; Feng X; Wang Z; Jin Y; Yang Z
Cancer Chemother Pharmacol; 2020 Jan; 85(1):185-193. PubMed ID: 31745591
[TBL] [Abstract][Full Text] [Related]
18. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
19. PD-L1-targeted microbubbles loaded with docetaxel produce a synergistic effect for the treatment of lung cancer under ultrasound irradiation.
Li T; Hu Z; Wang C; Yang J; Zeng C; Fan R; Guo J
Biomater Sci; 2020 Mar; 8(5):1418-1430. PubMed ID: 31942578
[TBL] [Abstract][Full Text] [Related]
20. Assessing the Impact of Phytochemicals on Immune Checkpoints: Implications for Cancer Immunotherapy.
Power Coombs MR; Hoskin DW
Methods Mol Biol; 2020; 2111():161-173. PubMed ID: 31933207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]